BridgeBio Pharma Announces Late-Breaking Oral Presentation Of Phase 3 PROPEL 3 Data On Oral Infigratinib In Achondroplasia At ESPE 2026 On September 9

Loading news article.

BridgeBio Pharma Announces Late-Breaking Oral Presentation Of Phase 3 PROPEL 3 Data On Oral Infigratinib In Achondroplasia At ESPE 2026 On September 9 | WAPE

BridgeBio Pharma Announces Late-Breaking Oral Presentation Of Phase 3 PROPEL 3 Data On Oral Infigratinib In Achondroplasia At ESPE 2026 On September 9

Article summary

Related companies

Comments —